👇🏽 Trial finding that led to approval:

Menin inhibitor revumenib showed promising efficacy in R/R NPM1-mutated AML — CR + CRh = 23%, ORR ≈ 47%, median DOR ~ 4.7 mo, manageable QTc prolongation.
📈 Led to FDA approval (2025) for R/R NPM1m AML.
#AML #Revumenib #MeninInhibitor doi.org/10.1182/blood.…